Camrelizumab
Camrelizumab (SHR-1210) is a potent humanied high-affinity IgG4-κ monoclonal antibody (mAb) to PD-1. Camrelizumab binds PD-1 at a high affinity of 3 nM and inhibits the binding interaction of PD-1 and PD-L1 with an IC50 of 0.70 nM. Camrelizumab acts as anti-PD-1/PD-L1 agent and can be used for cancer research, including NSCLC, ESCC, Hodgkin lymphoma, and advanced HCC et, al[1][2].
Product Specifications
CAS Number
1798286-48-2
Product Name Alternative
SHR-1210; INCSHR1210
UNSPSC
12352203
Target
PD-1/PD-L1
Type
Inhibitory Antibodies
Related Pathways
Immunology/Inflammation
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/camrelizumab.html
Purity
98.80
Solubility
H2O
Smiles
[Camrelizumab]
Molecular Weight
(143.69 kDa)
References & Citations
[1]Kuimin Mei, et al. Camrelizumab in combination with apatinib in second-line or above therapy for advanced primary liver cancer: cohort A report in a multicenter phase Ib/II trial. J Immunother Cancer. 2021 Mar;9 (3) :e002191.|[2]Jason D Lickliter, et al.A First-in-Human Dose Finding Study of Camrelizumab in Patients with Advanced or Metastatic Cancer in Australia. Drug Des Devel Ther|[3]Caicun Zho, et al.Camrelizumab plus carboplatin and pemetrexed versus chemotherapy alone in chemotherapy-naive patients with advanced non-squamous non-small-cell lung cancer (CameL) : a randomised, open-label, multicentre, phase 3 trial. Lancet Respir Med. 2021 Mar;9 (3) :305-314.
Shipping Conditions
Blue Ice
Storage Conditions
Store at 4°C for 2 years, do not freeze
Scientific Category
Inhibitory Antibodies
Clinical Information
Launched
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
![CD8A Mouse Monoclonal Antibody [Clone ID: CC63]](https://cdn.genprice.uk/products/937/68dd189a061270361e8fbc1a/imageurl/am05901fc-n.webp)
AM05901FC-N 100 Tests
CD8A Mouse Monoclonal Antibody [Clone ID: CC63]
Sign In for Pricing
View Details 